CED Cannabis Science Digest: 3 Safety, Stigma, and Potency Signals Worth Watching
The 2026 cannabis safety stigma potency digest reviews three important human studies on medical cannabis adverse reactions, youth potency-related mental health risks, and stigma in chronic pain care. These studies provide context and caution signals for…
Cannabis Testing Challenges Persist as Virginia Retail Market Nears
Virginia cannabis testing challenges create uncertainty about product potency and safety as the retail market launch nears. Lack of standardized testing protocols impacts clinicians' ability to counsel patients effectively. This issue highlights the need…
Understanding Rising THC Concentrations and Patient Safety
Rising THC concentrations in cannabis products significantly affect dosing precision and patient safety. Clinicians must understand these changes to optimize therapeutic outcomes. This article discusses the implications of rising THC concentrations for…
Texas Hemp Industry Legal Dispute Challenges State THC Testing Rules
The Texas hemp industry legal dispute centers on state THC testing rules that create regulatory conflicts. These testing discrepancies affect hemp product legality and patient safety. Industry representatives challenge state regulations to resolve these…
Potent Pot Fuels Psychotic Episodes, ER Visits: ‘America Has a Marijuana Problem’
Psychotic episodes emergency visits have increased with the rise of potent cannabis products. This correlation highlights the clinical risks associated with high THC cannabis use. Clinicians must update screening and risk assessment protocols accordingly.
Canopy Growth Targets Value Segment With High-THC Deelish Brand Launch
The high-thc cannabis value segment is expanding with Canopy Growth's new Deelish brand launch. This trend raises clinical concerns about accessibility and safety. Understanding high-thc cannabis products is crucial for patient safety and market…